AI-assisted international press reviewPress review

Sanofi Approves Qfitlia and Cablivi in China for Rare Diseases

Sanofi innovates in the treatment of rare diseases in China: Qfitlia, the first therapy reducing bleeding in hemophiliacs with only six annual injections, and Cablivi, targeting a severe coagulation disorder, receive approval. These advancements enhance access to care for over 40,000 patients, marking a significant commitment from Sanofi to transformative and accessible medicine. Promising clinical results show a significant reduction in risks, ushering in a new era for hematological disorders.

Source: Sanofi, published under the title "Press Release: Sanofi’s Qfitlia and Cablivi approved in Chin..." - 11 December 2025

UGL Launches Phase 3 of Western Downs Battery for Neoen and Tesla

UGL accelerates the energy transition in Australia: Selected by Neoen and Tesla to construct Phase 3 of the Western Downs battery, featuring 305 MW / 1,220 MWh of storage. This project involves the installation of 312 Tesla Megapack units, enhancing grid stability and renewable integration, following the success of Phases 1 and 2. A major advancement for a greener Queensland, scheduled for 2027/28. UGL, an expert in energy infrastructure, continues its innovative partnership in the era of giant batteries.

Source: Hochtief, published under the title "CIMIC’s UGL to deliver Stage 3 of NEOEN’s Western Downs Batt..." - 11 December 2025

Mars Acquires Kellanova: A Revolution in Sustainable Snacking!

Mars acquires Kellanova: An iconic merger to revolutionize sustainable and innovative snacking. This historic transaction unites two giants of the food industry, combining iconic brands like Pringles, Cheez-It, and M&M's to accelerate plant-based and sustainable innovations. With a focus on cereal and plant-based products, Mars strengthens its commitment to responsible eating while expanding its global reach to better serve consumers. A key step towards a greener future in the snacking industry.

Source: Mars Incorporated, published under the title "Mars Completes Acquisition of Kellanova" - 11 December 2025

Building the Future of the Workforce in Queensland

CPB Contractors is revolutionizing construction training: in partnership with Year13 and Construction Skills Queensland, discover their virtual experience program! Follow engineer Andrew Russell on a real project and explore the opportunities in a booming industry in Queensland, with record investments of $116.8 billion for infrastructure. A key initiative to build a sustainable future and train the workforce of tomorrow. Link: https://lnkd.in/g4vEDAKe.

Source: Cimic, published under the title "Helping build Queensland’s future workforce" - 11 December 2025

UGL Selected for Phase 3 of the Western Downs Battery in Australia

UGL has secured the contract for Phase 3 of the Western Downs battery in Queensland, in partnership with Neoen and Tesla. This ambitious project will add 305 MW / 1,220 MWh of storage capacity through the installation of 312 Tesla Megapack units and high-voltage infrastructure. Building on its successes in previous phases, UGL enhances grid stability and accelerates the transition to clean energy in Australia, with work set to commence in February 2026. A key milestone for sustainable energy innovation.

Source: Cimic - 11 December 2025

Bechtel Extends Contract for WIPP: Exemplary Safety and Performance

Bechtel has extended its contract for the Waste Isolation Pilot Plant: Exceptional performance enhances the long-term safety and reliability of the U.S. defense nuclear waste repository, with significant infrastructure advancements and zero major incidents. Budget savings and exceeded targets reaffirm Bechtel's sustainable commitment to a safer environment.

Source: Bechtel, published under the title "Bechtel Secures Three-Year Contract Extension at Waste Isola..." - 11 December 2025

Soils, Inputs & Water

Nutrien Completes Sale of Its Stake in Profertil S.A. for $600 Million

Nutrien Ltd. has announced the completion of the sale of its 50% stake in Profertil S.A., a key player in nitrogen production in Argentina, to Adecoagro S.A. and the Asociacion de Cooperativas Argentinas Coop Ltda. This transaction, valued at $600 million, is part of a strategy to simplify its portfolio and aims to enhance the quality of the company's earnings. The funds generated will be reinvested in growth projects, share buybacks, and debt reduction, reflecting Nutrien's commitment to improving its long-term profitability.

Source: Nutrien, published under the title "Nutrien Completes Sale of Equity Position in Profertil S.A." - 10 December 2025

Soils, Inputs & Water

Rovensa Next Launches Myndra: A Biostimulant for Exceptional Fruits!

Rovensa Next launches Myndra: the revolutionary biostimulant derived from Ascophyllum nodosum algae to enhance fruit quality in perennial crops. Through a cold extraction process without chemicals, it improves firmness (+19%), sugar content (+10%), and fruit weight (+19%), while increasing marketable yield. Certified by EU Regulation 2019/1009, Myndra aligns with a sustainable strategy for innovative and environmentally friendly agriculture. Trials on stone fruits, pome fruits, citrus, and table grapes confirm these benefits, enhancing the value of premium harvests. A major breakthrough for agritech!

SEPEHR ACHARD, Source: Igronews, published under the title "Rovensa Next Launches Myndra Biostimulant to Enhance Fruit Q..." - 10 December 2025

Thiess Drives Queensland's Largest Copper Mine Forward

Thiess and Harmony join forces for the Eva copper mine project in Australia: a 700 million Australian dollar contract for earthworks, construction, and mining services over five years. This strategic partnership emphasizes sustainability, energy efficiency, and local development, promoting employment, training for Indigenous communities, and a transition to clean energy. Initial works have been underway since May 2025, with mining services planned until 2031.

Source: Grupoacs, published under the title "Thiess to boost Queensland's largest copper mine" - 10 December 2025

Thiess Wins $700 Million Contract for Eva Copper Mine

Thiess and Harmony join forces to revolutionize sustainable copper extraction at the Eva Copper project in Australia. With extensive work planned over five years, valued at A$700 million, this partnership emphasizes efficiency, safety, and local development, while promoting employment and indigenous communities for a greener future. Innovative benchmarks are on the horizon for the mining industry!

Source: Hochtief, published under the title "Thiess secures A$700 million alliance agreement with Harmony..." - 10 December 2025

GSK'227 Receives Orphan Drug Designation for SCLC from FDA

GSK has received orphan drug designation for risvutatug rezetecan in the treatment of small cell lung cancer (SCLC). Supported by preliminary clinical data showing durable responses in patients with extensive-stage disease, this advancement highlights the urgency in addressing an aggressive cancer with high relapse rates and a grim prognosis. GSK's fifth regulatory designation accelerates the development of this promising candidate for solid tumors, paving the way for transformative treatments.

Source: Gsk, published under the title "GSK’227, a B7-H3-targeted antibody-drug conjugate, granted O..." - 10 December 2025

Thiess and Harmony Partner for the Eva Copper Mine Project in Australia

Thiess and Harmony join forces for the Eva Copper Mine in Australia: a $700 million contract for earthworks, construction, and mining services over five years. This strategic partnership emphasizes sustainability, efficiency, and energy transition, with a strong commitment to local employment, indigenous community development, and responsible mining innovation. Initial works have been underway since May 2025, leading to full operations by June 2026.

Source: Cimic - 10 December 2025

First in Australia: North East Link Certified PAS2080

CPB Contractors and the SPARK consortium mark a first in Australia with the North East Link project: the first infrastructure certified PAS2080, the global standard for carbon management across the entire lifecycle. Through a collaborative approach, they integrate 100% renewable electricity, recycled materials in concrete, and a commitment to net zero emissions, demonstrating a real step towards sustainable infrastructure for the benefit of communities.

Source: Cimic, published under the title "North East Link achieves Australian-first sustainability mil..." - 10 December 2025

ExxonMobil Revises Its 2030 Plan for Increased Profits

ExxonMobil announces a revision of its 2030 plan, aiming for a $5 billion increase in profits and growth in cash flow, without raising capital expenditures. The structural cost reduction plan has been raised to $20 billion compared to 2019, while greenhouse gas emission intensity targets are expected to be met as early as 2026.

Source: Exxonmobil, published under the title "ExxonMobil raises its 2030 Plan – transformation delivering ..." - 9 December 2025

CPB Contractors Integrates Broad to Enhance National Projects

CPB Contractors integrates Broad Construction: A strategic merger in 2025 to enhance construction expertise. New projects in key sectors such as education, defense, and health are now under the national banner, while ongoing projects in Western Australia and Queensland remain under the Broad name. This union strengthens capabilities, leverages 30 years of agility and exceptional results, with an unwavering focus on safety and unmatched client benefits. A decisive step for innovation in building.

Source: Cimic, published under the title "Integration strengthens national building capability" - 9 December 2025

AskBio Receives Pioneering Designation for Parkinson's and Heart Failure Therapies in Japan

The SAKIGAKE designation in Japan propels AskBio's innovative gene therapies, such as AB-1005 for Parkinson's disease and AB-1002 for congestive heart failure, accelerating their development and providing concrete hope for patients suffering from these serious chronic conditions, through a pioneering approach that combines advanced biotechnology and expedited regulation. This advancement strengthens the global commitment to targeted and sustainable treatments.

Source: Bayer, published under the title "AskBio’s AB-1005 and AB-1002 Receive Pioneering Regenerative..." - 9 December 2025

Novartis' Kisqali: 25% of Patients Without Progression After 4 Years

Novartis reveals: Kisqali allows one quarter of patients with advanced HR+/HER2- breast cancer to remain progression-free for at least four years, according to an analysis of the MONALEESA trials. This innovative treatment, unique for its significant overall survival, also reduces the risk of recurrence in early-stage cancer, as shown by NATALEE data. Presented at the San Antonio Symposium 2025.

Source: Novartis, published under the title "1 in 4 metastatic breast cancer patients treated with Novart..." - 9 December 2025

AgrifoodNorth America

Pairwise Shapes the Future of Food with NTG Innovations

As the European Union debates the deregulation of new genomic modification techniques (NGM), the American company Pairwise accelerates its strategic partnerships with Crispr/Cas, including its recent agreement with IRRI. Leveraging its Fulcrum platform and SHARC enzyme, Pairwise promises rapid agricultural innovations that are "non-GMO" – a claim contested in Europe, where these methods are regulated as such. These alliances, involving both public and private actors, could soon shape access to NGM and the arrival of new modified foods on our plates, raising ethical and regulatory questions.

Source: Info Ogm, published under the title "Pairwise façonne l’alimentation du futur à la sauce NTG" - 9 December 2025

Turner Develops Innovative Hospital in Memphis

Regional One Health is transforming Memphis with a state-of-the-art hospital campus in the Edge District, expanding critical care services from trauma and burn care to women's and children's health. With partners like Turner and HDR, this innovative project is generating 3,600 construction jobs and boosting the economy, enhancing access to care and health innovation for the Mid-South. A historic investment for a healthier future.

Source: Grupoacs, published under the title "Turner to develop new Regional One Health hospital in Memphi..." - 9 December 2025

TECVAYLI® and DARZALEX FASPRO®: Promising Advances in Multiple Myeloma Treatment

The results of the MajesTEC-3 study reveal that the combination of TECVAYLI® and DARZALEX FASPRO® offers significant benefits in terms of progression-free survival and overall survival for patients with refractory multiple myeloma, with response rates and minimal residual disease negativity significantly higher than those of standard treatments. Johnson & Johnson is committed to accelerating the approval of this therapeutic combination, which could transform current treatment practices.

Source: J&j - 9 December 2025